Trials / Completed
CompletedNCT00144612
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 2 Years – 19 Years
- Healthy volunteers
- Not accepted
Summary
An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRA(Tocilizumab) | 8mg/kg/2weeks |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2005-06-01
- Completion
- 2009-06-01
- First posted
- 2005-09-05
- Last updated
- 2009-12-23
Source: ClinicalTrials.gov record NCT00144612. Inclusion in this directory is not an endorsement.